Latest / Ensombl Advice Australia / Investment Podcast #41 - Beyond the AI Hype
Transcript
- 0:00The Ensemble podcast is intended for professional financial advisors. This content is created in partnership with our sponsor, Orbis Investment Advisory Pty Ltd, ABN 15101 387 964, AFSL 237 862, and is limited to publicly available information. Before acting on any general advice, you should consider whether appropriate and obtain financial advice from a qualified financial advisor. Ensemble does not hold an AFS license and does not provide any financial advice or services or endorse any general advice.
- 0:29If a PDS or IM exists, you should obtain a copy and review it thoroughly before making a decision. Past performance is not a reliable indicator of future results.
- 0:41How are you now? And welcome to the Ensemble Investment Podcast. My name is James Whelan, Head of Wealth and Distribution at InvestHouse AI. And I'm here to represent you, the humble advisor, doing their best to walk the line between client interests and asset class selection. We're trying to find the things that are not only appropriate, but they're actually working to be in the right things at the right time, the right way for the right clients. So get set because we are going to do our absolute best to answer some of the questions that have come up on the Ensemble platform. All information contained is general in nature. So here we go.
- 1:13Orbis has been investing in undervalued global stocks globally for over 30 years, focusing on long-term potential rather than short-term performance. Their team of 60-plus investment professionals focuses on unearthing companies trading below their true value rather than timing market trends.
- 1:28With over $80 billion Australian dollars in assets under management, Orbis has consistently applied the same fundamental, long-term and contrarian approach since its inception. In today's rapidly changing investment landscape, Orbis' contrarian style and high-value exposure can make it an effective diversifier in client portfolios.
- 1:46How are you now? Welcome back to the Ensemble Investment Education Podcast Series. I am your host, James Whelan. Whenever a groundbreaking new technology hits the market, investors throw out the rule book sometimes. I've seen this many times. We saw it with the railways. We saw it in the dot-com era. You're going to go back a long time and talk about tulips. I guess you could do that too. Now with generative AI and weight loss drugs, which are helping my mates out.
- 2:09History has shown that while technology shifts are permanent, the first market winners rarely endure, and paying peak prices usually ends in capital destruction. A similar cycle plays out in healthcare. Following the 2020 funding boom, and that was a lot of fun, we ended a severe what's called a biotech winter, where the market completely abandoned genuinely revolutionary science.
- 2:30Joining me to cut through the noise and look at these sectors through a long-term valuation-driven lens is Povolos Dapkevicius. That's close enough? I got there. That's close enough. Okay. Who hails in from Orbis Portfolio Management in London. Povolos, thank you so much for joining us. How are you now?
- 2:47Very well, thank you for having me here. Okay, well, this is no exception. I'm really the smartest person in the room and I think that this is something that I can absolutely guarantee for now. A hell of a track record from your side as well and Orbis, a hell of a manager too. But by means of introduction, what do you do and how do you make money?
- 3:05Yeah, so thanks for having me. My role at the farm is leading our healthcare and technology research in the global investment team based in London. And as a farm, as you know, we're long-term fundamental contrarian investors. So we try to buy stocks that trade at a significant discount to intrinsic value. That gives us a margin of safety and opportunity to outperform the market over the long term. That's good.
- 3:29That's the best introduction you could possibly have. And so what do you oversee at Orbis? What's your sphere of excellence? So in the global investment team, we're focused by sector. And so I possibly am overseeing our coverage of the IT sector and the healthcare sector. And these recommendations and research goes to all of our strategies at the farm.
- 3:49Yeah. And I mean, covering the IT and the healthcare sector, you find that the – it's funny that the cycles will be difficult to manage, I suppose, with these ones. And we're going to touch on this, but the 2020 boom, the cap in biotech with the mRNA boom.
- 4:04revolution and everything that was going on in that and then for it to go away. We're going to see what it's going to take to get that back. But I think that we are definitely seeing on the other side of the coin what's going on in AI and the IT revolution, these hyperscalers that may not have any more scaling to do and what the fallout from that is and the infrastructure behind it. So looking forward to digging into some of these things as we go too, which is great, Polis.
- 4:25Let's kick it off now. So your historical data on tech cycles shows severe underperformance when buying top decile valuation names. So if it's okay, because you walk us through what that data reveals. How does Orbis use an intrinsic value approach to find opportunities amongst the current AI euphoria?
- 4:43Yeah, so I think you're referring to one of the chats we included in our commentaries to clients. And the analysis we did was we looked at the top decile, most expensive shares in the IT sector over time and compared their performance relative to the entire sector. And it may not surprise you.
- 5:06the most expensive shares underperform over time. Yep. And most of that underperformance happens during times of crisis. So after the dot-com crash and after the COVID crash as well. Yep. Something for your listeners and investors to be aware of that valuation matters. And if you pay too high of a price...
- 5:28there's high expectations embedded in that price. And it's more likely that the future will present a disappointing outcome as opposed to a pleasing outcome for these shares. Yeah. And I think that going into the AI sector, just having a look at that, what's expected from some of these stocks and the valuations is either, first off, not possible, or well and truly overblown with regards to the expectations and what's being valued in some of these stocks. So I think that it's the idea of not buying the crazy valuation ones is probably
- 5:58going to be held to be true. But run us through the intrinsic value approach. How do you find the opportunities then based on that? So yes, okay, you can take out the top of their sales. How do you find the good stuff? Yeah. So I find that our intrinsic value approach kind of helps us avoid these shares quite naturally because we focus our work on understanding the companies, the industries they're operating in and assessing the intrinsic values. So thinking about the future cash flows that the business will earn,
- 6:25the competitive advantage that the company has, the management team, all of these good things. And so normally when we do all that work, we don't always get it right, of course. But on average, that keeps us away from the more expensive shares in the market. And it kind of leads us to the more interesting idiosyncratic opportunities where we're seeing something that the market is not appreciating.
- 6:46So that approach serves us well, I mean, frankly, in all sectors. That's what we do across all sectors, but it works very well in healthcare and IT as well. Keeps us out of trouble and allows us to spot those good opportunities.
- 7:02And we'll go into some of those opportunities just briefly, but if we can just get couching this conversation in the history, AI has been something that's been talked about for an extraordinarily long time, generations, but now has only really just popped out of the box from about, I'm trying to remember when the first ChatGPTs came out, 03? End of 2022. 2022. Yeah. That's right. It came out. From there, two years, a pretty significant thing. Yeah. Do you want to give us some sort of a historical context of how we got to this particular stage and maybe what you can see being...
- 7:30being ahead, generally speaking, for the space? Yeah. Yeah. So I think it's been very meaningful, like new technology that has come onto the scene, right? So in no way I would like to kind of underestimate what has been happening. And so initially, end of 2022, the first kind of version of ChatGPT hit and, you know, everywhere they found out about this new technology.
- 7:55And it was wonderful and kind of limited in certain ways. Basically, it was a one-shot approach where you'd ask a question and you'd get an answer back without much sort of thinking. Then two years later, we had the first reasoning model come out of OpenAI called O1. And so that was a game changer.
- 8:15Because effectively, the model would spend time at the inference stage. You know, after you ask the question, the model would ban tokens and think before answering. And unsurprisingly, if you give the model time to think, the answers come back at a higher quality and there's less hallucination. And so, I mean, we found...
- 8:34Internally, in our own research on the farm, that the technology became much more powerful and much more useful when the reasoning models came out. Yep. And then late last year, Anthropic released Opus 4.5 model, which step-changed the capabilities of their Cloud Code product. And so that was a game changer as well.
- 8:54I mean, the productivity and kind of the capability of writing software code, stuff changed dramatically. And I mean, you've seen the usage of that just went through the roof. I mean, Anthropic had an annual recurring revenue of $9 billion at the end of last year, which is now up to $47 billion. So it's more.
- 9:16than five times just the perfect time to get it on five months yeah yeah yeah so so in no way i would like to kind of minimize what's been happening in the world uh at the same time there's this wonderful wonderful book that i like it's called the engines that move markets and it goes through the past uh technological revolutions like everything from railways electricity radio internet
- 9:41And a few kind of messages that come out of that is even when you have very powerful technological revolutions, it's actually very difficult to pick the winners because the environment is very dynamic and the winners change all the time. And at any given point in time, it's difficult to know how the technology will fully play out.
- 10:03ultimately. And so that's a lesson probably to kind of keep in mind this time around as well, that the companies that we see as leading the current technological revolution may ultimately not be the ones who win the most out of it. I always, and people always stand when I use this as a general throwaway
- 10:23It's just an interesting thing. What number to the market was Google in the search engine market? We're going to talk about Google later, but talk about it now. It was the 13th. Yeah. It was the 13th search engine brought out, and it then became the biggest and the best. You would think that maybe one of the first five would have been the biggest, but it doesn't work that way. Yeah. First to market doesn't always win, and you've got to find the goals that are actually going to come through, and you're correct, and I like that. So let's get that book on the list there. What is it, the engines that move markets? Yes. Let's put it on the reading list, kids. Make sure it's there. Christmas is right around the corner.
- 10:52Do you think that maybe if we're talking now through the future of where AI is sitting, again, to couch this before we drill into a few names that we've got, do you think that companies are now struggling to find – or I'm hearing a lot of chatter at the moment, I should say, that companies are now struggling to find –
- 11:07if there were all of the benefits that maybe they were promised in some of this AI revolution. And I think that now that the costs are coming home to Bruce, especially as the token costs are really starting to bite, that they're starting to see that maybe bringing back some of those employees that they let go might not be the worst idea in the world to actually do the real work instead of having hallucinations come through. Yeah.
- 11:27So there's a lot on your question, I think. Sorry, I lighted up nicely. The thought that comes to my mind, I mean, NVIDIA CEO Jensen has spoken about it a number of times, which I think is kind of apt and worth mentioning in a response to your question. People thought that radiologists would be put out of business because AI would be so good at reading the scans. And actually, now we find ourselves in a shortage of radiologists in the world because, you
- 11:55AI-empowered radiologists as opposed to replacing them. I think we'll see a lot of that with generative AI as well. And so there was a concern that software developers would be out of business and, you know, these jobs would go away. In my mind, I mean, the world is quite short of software. That was something that probably we would have had a lot more had we had the supply of it.
- 12:19Now, tools like Cloud Codes have enabled us to have much more supply because software developers can be much more productive. And so I think the world will use more software as opposed to getting rid of these people.
- 12:35I think that there's a way of making sure that you own the pipes and plumbing for these things and maybe not being on the cutting edge, but definitely I'd rather be selling the tools that build some of these things, which is my model, but I'm not the guy running the money. Let's run through the actual process because I'm a process guy. What are the specific indicators that tell your team that a stock's long-term cash flows are being mispriced by the market?
- 12:57And then we'll get to some real names too, because then we'll talk about some stuff here. Sure. So I think one of the guiding principles is that not all growth is valuable. The company needs to earn more than its cost of capital for that growth to be valuable for the shareholders. And so we spend quite a bit of our time thinking about the competitive advantage that the company has, how good the management team is in adapting and guiding the company through what is a period of
- 13:27very fast change in the technology markets. So that's something to pay as much or even more attention to than just the multiple that the stock is trading at nowadays. So something to keep in mind. Other than that,
- 13:44I mean, we do the best we can in terms of forecasting what the company's fundamentals are going to be in the future. I mean, obviously, it's very uncertain. And so that's why we pick our spots and try to align ourselves with good management teams and strong businesses and the companies that we think are in a position to capture the value that they generate as opposed to it being competed away. Okay. And so let's go into a specific name here.
- 14:10If I have one more person tell me about SK Hynix, I'm going to scream. But SK Square, so you've got SK Square in the portfolio. That's got a 20% holding in Hynix? That's correct. Run us through, first off, give us an idea of what it is that they do. So SK Square is the holding company, is the investment company that is probably similar to SoftBank? Would we take those terms? Not quite. No, not quite. Yeah. Okay. Okay.
- 14:35Sorry, it's your shop. Rise through what they do. Yes. So most of what they do is hold SK Hynix. Yeah. Well said, especially the way that it's been cracking along. There's a few other small investments that they have and they'll make more in the future, but the vast, vast majority of the value of that holding company is the 20% stake in SK Hynix. Yep. And so the interesting thing is that
- 15:02SK Square is trading at a 50% discount to the value of their assets, the vast majority of which is SK Hynix, as we said. Kids bigger and bigger. So effectively able to buy SK Hynix at half price. And SK Hynix itself is trading at about six times earnings. And so with that 50% discount, you're effectively buying it at three times earnings, which doesn't scream as expensive for us.
- 15:28Yeah, it definitely sort of softens it down. Same market, same direction, same currency risk. Absolutely. That you have in there as well. And what are they, so they're in the AI hardware supply chain, that's Hynix is in that space? Yeah, SK Hynix makes memory. So the fact of DRAM and NAND, two kind of main forms of memory. Yeah, and they're currently looking at potentially a dual listing over into the states as well, which is going to open up pretty significant liquidity for them too.
- 15:54That's right. That could be a catalyst for the shares to re-rate closer to where the Western PIA is trading, which is Micron in the US. So that could help in unlocking some value. SK Square itself has a goal of reducing the discount at which the shares trade.
- 16:15So right now, as we mentioned, it's trading at a 50% discount and their goal is to reduce that to 30% over time. In our view, they're serious about it. They're buying back shares, which has the effect of gradually closing that discount. Yep. So buybacks, potential dividends to pay? Yeah. Good. Always a good thing to happen. But mostly prioritizing buybacks because of that discount.
- 16:38So, yeah. So, run us through the process that you got to that to have the investment going into SK Square. How long ago was the investment mode? Ah, good question. I'd say like a couple of years ago. So we were involved with the memory stocks and just kind of came to attention to one of our portfolio managers said like, well, why don't we buy SK Square, which trades at that time, it was trading actually at 65% discount to its net asset value.
- 17:08So it was just enormous discount, right, to the assets. And it wasn't difficult to value the assets because, as we said, most of it is just SK Hynix, which we already knew and had a favorable view on its fundamentals. And we thought that SK Hynix itself was quite undervalued at the time.
- 17:26So that's what led us to the shares. And then, I mean, part of the value of being a global investor is that we can see what's happening in one market. And, you know, sometimes a similar thing starts happening in another market. So you may recall in Japan, we had...
- 17:43very nice corporate governance reforms where Tokyo Stock Exchange led a number of initiatives where effectively they instructed the companies that traded below their book values to do something about it and be a little bit more proactive at improving their valuations and setting ROE targets and shareholder return policies. And over time, that led to an unlocking of
- 18:08shareholder value in Japan. And then we started seeing the same thing happen in Korea, where they have a value up program. And there's a number of things that government did, but a few interesting ones is they also encouraged the companies to have clearer shareholder return policies and be explicit about how much of their profits they're going to return to shareholders. Mm-hmm.
- 18:30And there was another interesting sort of legislational regulation come out, which made the directors of these companies to have fiduciary responsibility to all shareholders, which improved the minority shareholder protection rights. Yep. So we think of the backdrop of what's happening.
- 18:52happening in Korea with corporate governance is very favorable towards improving shareholder protection rights and closing kind of these holding company discounts that we're seeing in SK Square. Perfect. And so let's move. I mean...
- 19:07What's happened to the COSP over the last month or so is absolutely ludicrous, that market. So that's – and at least you know that you're getting a good fundamental market and governance around it as well, which is important. Let's turn now to Taiwan, a holding that you've had for about a decade now, TSMC. One of my old favorites, this one. So you've outlined –
- 19:27I've got a commentary here from March this year, as you outlined in this. So, Maurice Chang pioneered this pure play foundry model back in 1987. You know that in Australia, you used to have a semiconductor industry? You know what happened to that? Anyway, why don't you walk us through that history, if you can really quickly, TSMC. And this is one of your favorite holdings. But how did their customer-centric culture build the unbreakable moat four decades later? Yeah. So, TSMC is a company we have a lot of respect for. We've followed it over a long period of time. And
- 19:56It's been wonderful to see how the company developed. And as you mentioned, they have very strong customer centricity. They partner with their customers. They have a commitment to not take advantage of customers, even when the capacity is tight. And they could technically raise the prices, but they don't do that. And so that customer friendliness and that partnership attitude has served them very well. And they have...
- 20:24effectively like all of the largest semiconductor design companies work with them and effectively are enabled by TSMC so giants like Apple, NVIDIA Broadcom, AMD all of these companies are
- 20:40Our customers move the SMC. And so effectively, without the SMC, these companies wouldn't be able to produce the products that they produce. Yep. It's a pipes and plumbing. I'd much prefer to get involved in that back end, the foundation of what the rest of the market sits on.
- 20:56That's been our approach as well. We feel that we need to make fewer guesses on who the ultimate long-term winners are going to be, because if you think about it, no matter which of these semiconductor design companies end up winning the markets, whether that's NVIDIA or Broadcom or Google with its own chips,
- 21:15And all of that, or most of that, is produced by TSMC. With few alternatives, there are a few companies which are trying to compete with TSMC at the leading edge, but they're much smaller than TSMC is right now. Did Arm come up, when Arm went public a couple of years ago, I think it was now, did that come up on your radar as a potential case?
- 21:38For the same reasons, similar reasons? So normally we don't jump on IPOs. That's fair enough. Okay. That's fair enough. Yeah, okay. They tend to be well marketed. We have no comments on it. And well priced. Yeah. Yes. Okay. Well priced. Very well priced. But we'll look shifting on. We've got a few to get through here. So you've identified Nebius as a compelling play in the infrastructure space. Walks through the fundamental case for that.
- 22:07Where does it fit into the broader AI ecosystem? Yes. So, Nebius is a very interesting company, but maybe it's kind of less familiar for your listeners. On this list, yeah. There's a couple of names here that I had not heard of before that were guys. So, I'm keen to hear what's up here. Hopefully.
- 22:23I can tell you something new today. Excellent. So it's a rather interesting situation. The management team of Nebius is the ex-Yandex team. And so Yandex still is the dominant such engine in Russia.
- 22:39And so when the war in Ukraine happened, this management team restructured the company, sold the Russian assets, exited Russia, and reestablished the company in the Netherlands. Basically, at the time, they had a pile of cash, $2 billion, and a data center in Finland, a couple of non-core assets, which are quite valuable. Just bags of rubles stuffed under those.
- 23:02So quite an interesting kind of new beginning for this management team. But what attracted us to the situation is that if you think about it, this management team, they beat Google in Russia in a fight that actually was probably a little bit unfair towards Yandex because Google owned…
- 23:23Android, which is the dominant mobile software system, which helped them to protect their search business. And notwithstanding that, Yandex had the leading share in search in Russia. So we had a lot of respect for that team. And they have...
- 23:42very high technical ability. So when they emerged after that restructuring, we engaged with them. There was a capital raise that we participated in together with NVIDIA and Excel, which raised $700 million for them. And it kick-started their business, which is AI cloud infrastructure.
- 24:02So we felt that this is the team which has the technical capabilities to build a large business in this area. It has the relationships, both with the customers, with NVIDIA, ability to raise capital. So we saw all the ingredients in place for them to build a large business in that space. And clearly, there is a lot of demand for that.
- 24:25type of service uh the supply and demand is is is very much out of whack um and and the moment they build a data center and switch on these gpus everything is sold out so that that that's kind of where we started with it um and that's so that's that's how long has that been on for that so just since the war just after the war so so we participated in the capital race at the end of 2024 okay
- 24:49So it's been a little bit less than two years since the company restructured, and they made huge progress. And so we think that another thing that was quite misunderstood and is still not well appreciated. So they participate in this whole space that people call NeoClouds. So kind of the NeoClouds, which compete with a hyperscalist like AWS and Microsoft Azure, Google's GCP. Mm-hmm.
- 25:16But the technical skill within that sector, within the neoclouds, is extremely different. You have companies which are effectively just reselling NVIDIA servers without adding much value on top of it, and what's called bare metal. So they just take a server, they resell it to the customers without adding much value. At the other end of the spectrum, you have companies like Nebius,
- 25:40which have a software layer on top of the hardware, which enables the AI developers to be much more productive immediately without having to configure the hardware, without having to worry that the hardware is running well, and that you're getting kind of maximum utilization, because these servers are very expensive. So there's a lot of value to be added by running them effectively. And so we believe that Nebius has the technical capabilities
- 26:08to run vSub as well, and ultimately to build a business that could be very large and compete with the hyperscalers. And that I could see too. So what sort of margins would they be running on? Sounds like a company like that would probably be about 70% or something like that.
- 26:22So off the top of your head, sorry. Yeah, no, I can answer that. They're lower than that. So it depends how you kind of look at the margins. But on after depreciation, which is the cost that you should take into account, because most of the cost is the depreciation of these servers. They're targeting 20% to 30% margins on an EBIT basis, so before interest and tax. That's what we think they're going to be able to do. And we can see in the economics that they have right now and kind of the business that they're signing. Yeah.
- 26:51Some managers that I talk to take a very – an arm's length approach when it comes to talking to management and dealing with management. Some of them are right in bed in there with them. And you mentioned that you reached out to the management team when they went to the Netherlands. How involved with the team are you, generally speaking, with companies like this? Are there some companies that you're not as involved with? I mean, I can't imagine Google is – you're on the phone to them every second day.
- 27:15I wish. I know. It's a nice to have, isn't it? But yeah. Yeah. But this team, they'd be giving you the heads up on things that were moving, see if it was in line with your ideas. So my own kind of philosophy on it is that it's very valuable to understand and have a relationship with management teams. Not because we're going to tell you something that they haven't told to anybody else. We obviously cannot do that.
- 27:38But it's the context around the business, understanding the ambition that they have, how to interpret the information that they're releasing. That can be extremely valuable. And so we try to engage with management teams as much as we can. And so we've been in close contact with this particular team a number of times, typically try to catch up with them after every earnings release and kind of in between as well.
- 28:07Okay. So we're going to move on because I actually realized we do have a fair bit to get through, which is good. So we're going to be running good for time here. I can now talk about this. I've got a friend of mine who was quite senior at Google for a while. He's not there anymore. And I remember saying, he was always telling me about exactly what, this is years ago, talking about exactly how Google is going to dominate the AI space. He said, we'll win, we'll win, we'll win. They've got the best stuff.
- 28:30And then when it all started to come out and it was seen that Google was slow, Google was behind, Google was not. And I actually asked him about it. I'm pretty sure that I can talk about this now. He said, if we released, it was always seen as if there were too slow releasing things. He said, if we released everything that we had right now, people would lose their minds.
- 28:45They actually were stalling the releases of what they had in the can because they were so far advanced and they didn't want to freak everyone out. Now, I don't know if that's true or not, but it's a great story. Yeah. I love a good story. So, yeah, in the contrarious style that you're famous for, you bought Alphabet when the market consensus did label it an AI loser. What did you see? What was the diamond in the rough? Is it something similar to what it was that I just said? Yeah. So, I hope you bought the stock when your friend told you that story. Yeah.
- 29:14Yeah, we got a little in the back pocket here. Yeah, so I would say maybe just kind of take a little bit of a step back. It was quite shocking how sort of caught by surprise they were when ChatGPT came out and how they seemed on the back foot and took a little bit of time for them to respond, which is, I think, why...
- 29:37the market took that view that they're going to be an AI loser because I think it was quite reasonable to worry about that. Now, we've owned the stock for many years, sort of on and off, not continuously, but when the stock would trade at a deep discount, we'd own it, and then the discount would close, and we'd move on to other shares. So we had a good level of familiarity with the company.
- 30:03And so what we started seeing was at some points, the management team got the act together. The execution improved. The Gemini model started gaining traction. Yeah. You could see the downloads go up, the number of users go up.
- 30:18AI overviews and such started working and kind of the metrics on search improved as well, like the number of clicks and the revenue growth. And it kind of started to become clear to us that that whole narrative that Google is an AI loser is just not going to play out, that they're actually well positioned.
- 30:37I should also mention that through our semiconductor research, we learned more and more about Google's TPUs, their own chips, their own AI accelerators. And we liked what we learned about it. I mean, these are very competitive products. They can go head to head with NVIDIA, which is a lot, says a lot. That says a lot. You go, if you're, what is it? If you get...
- 31:05There's a slanderous term for Jensen Huang, and I don't know what it's... They call him Tech Fonzie because he wears that leather jacket all the time. It drives me insane. But do you think that... Speaking on this one, do you think that NVIDIA is going to have its dominance chipped away because of the competitors that are building their own chips? I mean, it's a great question. Like, they're very dominant right now. I think they'll probably have to share that market with some other companies in the fullness of time.
- 31:29Now, that may not be such a bad thing for them because the market will grow as well. Yep. So, you know, you may have a slightly smaller slice of a bigger market. Yeah. And so I wouldn't be kind of negative about them. Yeah. Smaller slice of a bigger par.
- 31:46Exactly. Okay, I can see that. All right, we're going to have to get into the next stage. Now, we've talked about the beautiful euphoric heyday of artificial intelligence and everything in tech. Let's talk about the winter that's befallen the biotech space. 2020 was a hell of a year. Everyone was getting very edgy about these sorts of things. Sitting in my pajamas for most of the day, looking at some of these stocks absolutely ramp in the space. Yeah.
- 32:10Now, in your note here, I've got a note here from June 2025, you detailed just how the sector went from 2020 to the capital rush into a brutal sentiment freeze. It's heavily out of favor compared to IT. Could you walk us through why the sector-wide skepticism creates the opportunity that you potentially see for a value investor?
- 32:29Yeah, sure. So, I mean, what happened is that biotech companies were saving the world, right? I mean, everybody knew about the vaccines, the sales went through the roof. Now, the problem was, is that these vaccine sales, like, almost disappeared a few years later. And so there was a huge disappointment.
- 32:48I think a reality check that, I mean, biotech has a tech in it and it can be quite volatile and unpredictable. And so the sentiments became very bearish. And so what we're finding right now is that the expectations that are embedded in the shares are very low. It's a very rich opportunity set, which ultimately allows us to buy...
- 33:13Very high quality companies that are doing great science and bringing medicines to patients where there's a huge unmet need. They are run by very reputable management teams that are executing well. And we're paying very low prices for these type of companies, which is unusual. And I think a function of just how bearish the sentiment got in the space and how much the excitement has shifted into the AI space and sort of sucked all the oxygen out of other sectors.
- 33:43Yeah, I think that your money has to be with a certain amount of AI and it's just shifted. It has just drained it right out. So the vacuum that's created. So how do you pick out when you're dealing with a situation like this, how do you then go and pick out a winner and think, okay, this is actually a potential, got a potential upside, not just a value trap? Yeah, yeah. So one thing that we...
- 34:02really pay attention to and value in this sector. If you think about these companies deploy a huge amount of capital back into R&D. So you have certain products on the market and they're earning you profits. But then the companies are redeploying a lot of that and most of that back into R&D. Mm-hmm.
- 34:19And so the capital allocation skill and the quality with which management allocates capital is very important because ultimately you can run a DCF and think that this is free cash flow, but if the management team puts it back into the business, the returns that they'll generate is kind of what drives the shareholder value. Yep. So we spend a lot of time thinking about and engaging with the management teams, trying to understand the track records, how they made
- 34:48decisions in the past and what results that yielded, what are the current pipelines and what they're investing the money in. So that's something that we pay very close attention to. And then, of course, we look at current marketed products and the pipelines and what we want to see is...
- 35:06Drugs that are making big difference for patients, that they're addressing big needs and that they're differentiated, that they do something that their competitors' drugs cannot do. Well, let's get into some names here. And there's, like I said, a couple that I had not heard of before, which is great. That's why I'm going to pick your brain on this one. Genmab is the first one I've got here. So they've got an antibody discovery engine, but they do have a late 2020s patent cliff. Mm-hmm.
- 35:34on their flagship drug, which is Darzalex. So if you walk us through how the market is mispricing this asset in the face of that as well, are investors effectively getting their entire future pipeline for free? So the patent cliff is what is creating the opportunity here. What we find in the sector is that when the companies are approaching a patent cliff probably about like five, six years before the cliff,
- 35:55you have peak uncertainty because the market can see that you're going to lose revenues. And these revenues have very high margins. In this case, it is royalties on one of the largest drugs in the world called Dyer's Alex for multiple myeloma, which is being sold by J&J. And GenMap is getting royalties on that. So effectively, the gross margins of that are 100% or as close to 100% as you can get. So you can see what you're going to lose.
- 36:21But you can't quite yet see what will replace that. And that's what's creating the fear in the market because the company needs to invest in R&D, run the clinical trials. These need to be successful. And then once that happens, you know, you can rebuild your revenue base. So I'm assuming they have something in the power plant? Yeah.
- 36:40Yes, they do. Okay. That's an obvious question for you. So they have drugs on the market already. And then there's three pipeline compounds, which are currently in the phase three clinical trials. One of them is already on the market. And effectively, it's running trials to just expand its indications into the earliest stages of disease.
- 37:04um the drug is called epkinly typically that is a less risky type of trial because the drug has already worked in the later stages of the disease where the patients are sicker and more difficult to treat so if the drug worked in in in these settings it translates that there's a high probability of success for it to work in an earlier stage settings okay
- 37:25And they have a couple other oncology drugs, and oncology is an area that they focus on where we have good data sets from prior trials, and we understand the mechanism of action of these drugs, and we think that they have a good probability of success. Like, nothing is guaranteed in biotech, and one of them could fail. So we run our analysis on a probability risk-adjusted basis.
- 37:49And so when we do that work and we value these three late stage compounds and nothing else in the pipeline, no early stage assets, under our assessment, the stock is trading at half of its intrinsic value. Yeah. So we find that very attractive. It's a management team we respect a lot. It's run by scientists, founders, CEO, and very strong team around him. We had multiple interactions with him and the team and I think they highly of them. Yeah.
- 38:19So strong team, they've still got the Darzalic royalties coming in, as you mentioned as well. And they've got something that's on a risk-adjusted valuation metric does seem like it's a late-stage opportunity. Yeah. Great. Okay. So I think that investors often, when it comes to biotech, the frustration is just how binary some of these things are. It's either going to work or it's not. And if it doesn't work, it could potentially be a zero. And if it does work, then that's great. It's fantastic. But to value that risk is...
- 38:49It's difficult sometimes. It's definitely kind of a feature of these companies. Even the larger companies, they're still usually quite concentrated in a couple of assets. It's difficult for them to be fully diversified. So the way we deal with that is it's nice when the companies have a portfolio of assets. So not everything has to work out. If two parts of these assets work out,
- 39:18you're going to come out uh the winner or offset the losers exactly exactly so that gives you a certain margin of safety now in other situations where you're more reliant on a single asset it we have to limit the position size in these type of stocks and uh you know they if if we have skill and we do it well as a basket they'll they'll work well for us but any individual one can disappoint okay so let's um move along here um
- 39:43Alnilam Alnilam I'm getting this all over the place today Pharmaceuticals I can say that Pioneering RNA interference therapeutics So they're currently scaling Their next generation treatment Amvutra Amvutra Walk us through the science here What specific commercial growth catalyst Is the market missing
- 40:06Yeah, so there's a number of difficult to pronounce words with this company. So hold on for this. I mean, the disease that they're treating with Ambutra is called transphiretin amyloid cardiomyopathy. So that's quite a mouthful.
- 40:24Our biotech analyst compares it, kind of uses an analogy and says it's like the Alzheimer's of the heart. Got it. Because effectively the body is producing protein, TTR protein, and when that protein misfolds, it leads to accumulation of amyloid in the heart. And obviously that leads to a health issue.
- 40:47And so what Amvutra does is knock down the production of that protein. So if you have less of that protein, less of it misfalls and ends up accumulating in your heart and causing you an issue. So the drug is highly efficacious. It's approved. It's on the market in the US and a number of other developed markets in the world.
- 41:11And it's been launching very well. So we remain optimistic about Alnylam and the drug launch. We think it's still underappreciated for a couple of reasons. One is, well, everything.
- 41:26ATTRCM, which is the disease that I'm not going to try to pronounce again. We did. Yeah, we did. Okay. Yeah. It's a rare disease in the way it is classified, but it's less rare than people think. It's been difficult to diagnose in the past because it needed an invasive method. You basically had to put a stent into the heart to diagnose it. Yeah. Now you no longer have to do that. There are non-invasive ways of diagnosing the disease. Yeah.
- 41:52And so we think with better testing and more companies selling pharmaceuticals in that area, you just get more awareness, more education for physicians, more testing. And so the market will grow and more patients will be identified over time.
- 42:08Hopefully, the patients will also live longer. I mean, that's not being decisively proven in clinical trials, but if you think that these drugs are effective, which they have proven to be, patients should be living longer, and so that will grow the market size as well. Okay, so that's alnylam with the amvutra for ATT-SCM. ATT-SCM. Okay, got it there. And so mispricing exactly that, so growth in the drug being used and picked up with awareness is probably going to be the driver for that name.
- 42:38I mean, I would be remiss not to mention that they have a wonderful platform that can produce more RNAi drugs. It's a very differentiated drug discovery platform, which can silence the production of other proteins in the body. And so they're working on delivering that technology into various platforms.
- 43:02parts of the body. And so adipose tissue is one, so that could be helpful in obesity. And then they're working on delivering these medicines into the brain, which opens up entire new opportunities to treat different diseases, like Huntington's disease. Oh, wow. Okay. So that's one that I do know.
- 43:20Okay, so moving on now. So Scholarock, this one I had not heard of at all. So it's got a high upside clinical developments that it's working on. What's the core value thesis for Scholarock? And I've got a note here, their approach embodies a disciplined R&D engine, which I think that you wanted to have a talk about.
- 43:39So this is a, Skolrock is an interesting stock. I'll give you a little bit of history briefly. They have one main compound that they're working on and apetigromab. And so effectively this product is a myostatin inhibitor, which effectively promotes skeletal muscle growth in the body.
- 44:02And so they ran a trial for spinal muscular atrophy, SMA, and it was successful, it was efficacious and safe. And the drug is awaiting approval by the FDA. Now, what happened is that the drug is manufactured by Catalan in Indiana. It's a facility that is now owned by Novo Nordisk, the Danish pharmaceutical company.
- 44:24that facility had compliance issues with the FDA. And so FDA sent them a warning letter and said, like, you have to fix this. And what happens is when you have a facility that goes out of compliance, out of a good manufacturing practices with FDA, FDA does not allow you to approve, to get new drugs approved that the manufacturer did not facilitate. So nothing goes through. Exactly. So Scolarock gets caught in the middle of Catalan, an FDA, and cannot get its drug approved.
- 44:53even though the audit ran a trial and has been successful and efficacious and all that. And so it's interesting in the current kind of fragile sentiment in the biotech, you would think, well, what's the big deal? It's a little bit of a time delay because the facility will be brought back into compliance or an alternative manufacturing facility will be arranged, which the company is already doing, right? So you'll have a backup facility.
- 45:20And it's purely a timing issue. The company has communication from the FDA, which tells them that the regulatory agency doesn't have any kind of problems with the drug's profile, efficacy, safety, that the only kind of outstanding issue is a compliance of the manufacturing facility. So we like that type of setup because we're getting paid to wait. And in our assessment, we're not taking much risk because the trial has already been run and the drug has proven efficacious.
- 45:50I do like that style of investing as well. The best opportunities do come out of it. When I say to clients, we're about to talk about conversations with clients for the few minutes we have left here. Nothing has changed. The only thing that's changed is the price. The story hasn't changed at all. They've still got the drug. They're still capable of doing what they need to do. The only thing that's changed is the price, which is great. Having this conversation with advisors, because we are four advisors here who are listening. When clients want exposure to that future, they usually ask for the highest profile stocks for the most vertical charts, and they're going to be able to do that.
- 46:19annoyingly and frustratingly, but buying top decile valuation names has historically been a recipe for long-term underperformance, as we said at the top of the show. Can you walk us through, for the advisors specifically listening, how they can use these case studies like we've talked about with SK Square or the Out of Favor biotech names to reframe that growth conversation with their clients?
- 46:38Yeah, so I would say a couple of things. I think, you know, one, as that historical study showed, valuation matters. Valuation discipline matters. If you pay for high expectations, your future returns are diminished by that. So that's something to keep in mind for investors. And so as we spoke about today, I mean, we're finding a lot of opportunity in the areas of the market that are out of favor because expectations are low in these parts of the market. Mm-hmm.
- 47:07Not to say that there are no opportunities in the areas that people are excited about. We spoke about several AI kind of exposed stocks, which we think are still reasonably priced. So when investors look at these parts of the market, I think obviously they have to be more careful. They have to pick the management teams carefully, think about the valuation, think about
- 47:31the competitive advantage that the company has, the ability to capture value from the new technology that is kind of just broke on the scene. Because not all of the companies that look like winners today will ultimately prove to be the winners of tomorrow and generate big profits for clients. And we did say, so let's just stretch out into that a little bit more.
- 47:57Client boredom is a thing that I've faced for 20 years doing this. You can hold a stock. People just get bored with it. Nothing's happening, James. Come on, let's just move on to the next thing. Do you have any sort of metrics for conversations that people want to have, historical parallels to reinforce that value of patience? Absolutely. How do you keep people calm and sitting while they're going through a winter
- 48:18Well, it's hard, but I can tell you what helps us is tracking the company's progress as a business, not just as a stock and a ticker on the screen. Is the company making the right investments? Is the management team making good decisions?
- 48:34Are the profits growing? When we see that the companies are functioning well, making good decisions and growing profits, it makes it much easier to hold them during periods when the share price is doing nothing because the stocks are getting cheaper relative to the fundamentals which are growing.
- 48:52So I would say, you know, focus on companies as businesses and think like a business owner. Yep. That's often a good one to bring up too. Stop looking at the price. Look at the actual company. Look at the name. That's right. That is correct. And it's often, there's in the alternative one, if you have something like Orbis sitting there as well, it's not multiple lines that you see in there. It's just one line of the fund that's in there. But that's a different thing.
- 49:16Which may make it easier. You don't see some of that. Yeah. There's someone else. The Alan Gray boys often say that. It's just like it's a good line to have in your portfolio. So you don't have to offer all those individual lines in there. Because sometimes they can be a little bit ugly for people to look at. But it's good as that one there.
- 49:33going on with that. So, look, thanks very much for joining us. So, looking at both the semiconductor supply chain and the biotech winter, one up, one off, it's clear that patience, intrinsic value, discipline, willingness to be a contrarian takes guts, are the ultimate superpowers in a hypercyclical market. And thank you very much for bringing the perspective to our audience today. Thank you for having me today. Not a proud pleasure. Good idea. That was Povolos Dapkevich.
- 50:03I'm sorry. Duff Cavaliers. Duff Cavaliers. I get it again. From Orbis Portfolio Manager. Have a great time in Sydney and safe travel back to London. Thank you. I'm James Whelan here for Ensemble. Thank you, Kieran. A wonderful production as usual. Stay safe and all the best, everyone.